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Summary 
Advanced heart failure represents a significant strain on our health care system and is 
associated with increased morbidity and mortality. New device therapies, including left 
ventricular assist device (LVAD) implantation, have transformed management as both a 
destination therapy and as a bridge to transplantation. Although LVADs have improved patient 
outcomes, arrhythmias represent a significant and costly complication of this therapy. In recent 
years, implantable cardioverter-defibrillators (ICDs) have been developed to reduce the incidence 
of lethal arrhythmia. However, a gap in the literature exists for both guidelines in prevention of 
early ventricular arrhythmia (VA) in LVAD recipients and the effectiveness of ICDs when paired 
with various LVADs. Here, we clarify these guidelines and show that ICD selection should be 
tailored to the type of LVAD. We also show that subcutaneous ICDs represent an attractive 
alternative option for certain cohorts of patients, although transvenous ICDs remain a first-line 
choice at this time. Ultimately, understanding the various management options that affect 
outcomes in heart failure patients is important for treatment and clinical decision-making in an 
ever-growing population. 
Methods: PubMed was searched for various studies published from January 2001 through 
December 2020, using subject terms “implantable cardioverter-defibrillator” OR “ICD” AND 
“acute heart failure”, “left ventricular assist device” OR “LVAD” AND “acute heart failure”, 
“HeartWare OR HVAD”, “HeartMate II” OR “HMII”, “HeartMate 3” OR “HMIII”, 
“Transvenous ICD” OR “TV-ICD” and “subcutaneous ICD” OR “S-ICD”. Authors included case 
reports and series, retrospective and prospective studies, systematic reviews and meta-analyses, 
clinical guidelines, and narrative reviews. This PubMed search only included studies published in 
English and those with human subjects. Initial literature search revealed over 442 articles. 
References in the articles were also evaluated for discovery of potentially relevant studies. 
Authors reviewed relevant articles and decided which studies to include for this review, with a 
concentration on acute HF-relevant articles. A total of 39 resources were selected for inclusion in 
this review. 
Ventricular Arrhythmias in LVAD Patients 
Figure 1: Diagram of LVAD .1 Left 
ventricular assist devices are now 
commonly used in advanced HF to 
improve survival and reduce mortality. 
LVADs are used as both destination 
therapy (DT) and as a bridge to heart 
transplantation (BTT). LVAD 
implantation has been shown to result 
in prolonged ventricular repolarization, 
myocardial scarring and acute 
ventricular unloading, all of which 
have been shown to predispose 
patients to arrhythmias.1,2 
Figure 2: Number of early VA 
events. 3 In a group of 162 patients, 
24% experienced at least one early VA. 
Among patients who experienced an 
early VA, 34% underwent more than 
one event. Preoperative VA was the 
biggest clinical predictor of early VA; 
non-ischemic cardiomyopathy and 
advanced age were also statistically 
significant predictors for VA.3 
Contemporary LVADs and VA Risk 
H,eartware4 HMll5 t HMll l6 + 
Number of patiienls 26 106 515 
% of patients with VA § 35 35 21 
% of patients with VT 11- 27 32 -
% of patients with VF 1 8 13 -
l otal VA episodes 21 109 -
% of patients with early VA - 24 -
o/a of patients with llate VA - 18 -
Early VAs per patient-year 1 . .8 - -
Late Vas per patient-year 0.8 - -
†: HeartMate II, ‡: HeartMate III, §: Ventricular Arrythmia, ||: Ventricular Fibrillation, #: Ventricular 
Tachycardia 
Table 1: Summary of VA in LVAD 
Recipients. These data 
demonstrate that while 
HeartMate III (HMIII) recipients 
have a risk for VA after 
implantation, it is lower than 
patients who have been 
implanted with HeartMate II 
(HMII) or Heartware (HVAD), 
which suggests that the HMIII is 
less irritable to the heart.7,8 
Although no definitive 
conclusions have been reached in 
any study, possible reasons for 
this difference include 
differences in pump size, 
increased width of blood-flow 
pathways in HMIII, and HMIII’s 
intrinsic pulsatility diminishing 
shear stress and stasis of blood.8 
ICD Therapy and Types of Devices 
ICDs have transformed the management of HF patients by reducing the incidence of lethal arrhythmias and the 
risk of SCD.9,10 There are two main types of ICD devices, a transvenous ICD (TV-ICD) and subcutaneous ICD (S-
ICD), which may have different implications in LVAD patients. LVADs can cause electromagnetic interference 
(EMI), leading to sensing dysfunction in the S-ICD. However, EMI is more associated with HVAD and HMIII, 
with fewer cases occurring in concomitant S-ICD and HMII use.10 
A. B. 
Figure 3: Types of ICDs 
(A)TV-ICD and LVAD Diagram. TV-ICD and LVAD position in the chest. Left, Anterior view. Right, Lateral 
view. Advantages of the TV-ICD include the ability to deliver long-term bradycardia pacing and deliver anti-
tachycardiac pacing . 
(B) S-ICD and LVAD Diagram. S-ICD and LVAD position in the chest. Left, Anterior view. Right, Lateral view. 
Advantages of the S-ICD involve avoidance of an invasive procedure along with intravascular lead-related 
problems such as endocarditis and bacteremia. 
Current Approach to ICD use in LVAD Patients 
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Figure 4: VT-LVAD score . 12 The ASSIST-ICD study used 
the results of their observational study assessing the clinical 
predictors of late VA to create a score to stratify patient risk, 
the “VT-LVAD score”.12 They stated that high-risk and very 
high-risk patients should be considered for ICD therapy, 
while low-risk patients may consider forgoing ICD 
implantation due to the presence of a similar complication 
risk profile and a lower potential benefit. Although this 
study gives indications for the prevention of late VA, it 
takes no position on the prevention of early VA. 
Recommendations for Clinical Care 
Figure 5: Flow diagram of early VA prevention in LVAD recipients 
LVADs represent an important therapy for management of acute and chronic HF, 
however, they carry the risk of post-implantation VA. The HMIII appears to have the 
lowest risk of VA among its recipients (Table 1). 
ICD for primary prevention of early post-VAD VAs should be considered at the time of 
LVAD implantation in patients who present with acute HF or risk factors for early VA . Prior to 
ICD use, pharmacological therapy may be attempted, however, post-LVAD VAs often fail to 
respond to antiarrhythmics. Despite the inherent risk associated with transvenous leads, TV-
ICD should be considered a first-line treatment modality at present until the role of S-ICD is 
further evaluated in larger studies. S-ICD may be a viable option in patients with an 
exceptionally high risk of bloodstream infection or in patients with prior HMII use. 
Future Directions 
• Prospective, randomized trials directly comparing VA incidence in HVAD, HMII, and HMIII 
• Further investigation and refinement of S-ICD sensing algorithm when used with different
LVADs 
• Randomized trial data in both BTT and DT patients to determine optimal device indications in 
LVAD patients at risk of VA.
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